GlaxoSmithKline News and Research

RSS

New imaging technique catches arthritis early

You come into a doctor's office with severe knee pain. The physician orders an MRI, which reveals substantial loss of cartilage - osteoarthritis, that is - in your knee joint. At this point, not much can be done beyond gulping down palliatives and trying to keep your weight off the joint. But the damage may have started building as much as 20 years earlier, possibly due to a traumatic injury to the affected joint.

29 Jan 2009

GSK and XenoPort resubmit NDA for Solzira in restless legs syndrome

GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

12 Jan 2009

GSK completes tender offer for shares of Genelabs Technologies

GlaxoSmithKline plc has announced the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares of common stock of Genelabs Technologies, Inc.

7 Jan 2009

Nicotine gum effective for gradual smoking reduction and cessation

Nicotine gum has been in use for over 20 years to help smokers quit abruptly yet close to two-thirds of smokers report that they would prefer to quit gradually.

6 Jan 2009

Watson Pharmaceuticals receives FDA approval for mint coated nicotine gum

Watson Pharmaceuticals, Inc. has received approval from the United States Food and Drug Administration to market its over-the-counter Nicotine Polacrilex Gum USP, coated mint flavor, in the 2 mg and 4 mg strengths.

1 Jan 2009

Immunogenicity and safety of human papillomavirus vaccine in healthy boys

New industry-supported research from Finland suggests that Cervarix, an HPV vaccine given to girls in Europe and elsewhere, is safe for boys as well.

21 Dec 2008

GlaxoSmithKline ready to supply Biota's Relenza to meet CDC recommendations

GlaxoSmithKline (GSK) is prepared to respond to public health needs for Relenza (zanamivir) Inhalation Powder this flu season following a Health Alert Advisory issued by the Centers for Disease Control and Prevention (CDC).

21 Dec 2008

Two common biomarkers help predict stroke risk

Two common biomarkers have now been shown to improve the ability to predict who will suffer from a stroke.

18 Dec 2008

GlaxoSmithKline extends Genelabs acquisition offer

GlaxoSmithKline has announced that it has extended its previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc., for $1.30 in cash per share without interest and less any required withholding taxes, until 5:00 p.m. New York City time on Monday, December 29, 2008, unless the tender offer is further extended.

17 Dec 2008

GlaxoSmithKline statement on FDA advisory committee vote on use of asthma medicines containing long-acting beta agonists

The following is GlaxoSmithKline's statement regarding recommendations of a combined Advisory Committee to the FDA on the use of asthma medicines containing long-acting beta agonists, including GSK's Serevent (salmeterol) and Advair (salmeterol/fluticasone proprionate).

14 Dec 2008

$Thiazolidinediones doubles risk of fractures in women$

Thiazolidinediones doubles risk of fractures in women

New findings out of Wake Forest University School of Medicine and the University of East Anglia show that long-term use of a popular class of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes.

10 Dec 2008

Vaccine against malaria could be ready in 5 years

Malaria kills more than one million people every year so the news that an effective vaccine could be available within five years is more than welcome.

9 Dec 2008

GlaxoSmithKline extends Genelabs offer

GlaxoSmithKline has announced today that it has extended its previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. for $1.30 in cash per share without interest and less any required withholding taxes, until 12:00 midnight EST on Friday, December 12, 2008, unless the tender offer is further extended.

8 Dec 2008

Promising trials of malaria vaccine in East Africa lead to calls for phase 3 development

Experts are recommending that a malaria vaccine progress to Phase 3 trials following the successful trial of the RTS, S/AS01E malaria vaccine among 5-17 month old children in Korogwe, Tanzania and coastal Kenya, which is reported in the New England Journal of Medicine (NEJM).

8 Dec 2008

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

GlaxoSmithKline has announced positive safety and efficacy results from RAISE (RAndomized placebo- controlled ITP Study with Eltrombopag), a Phase III study of Promacta (eltrombopag) in adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who had received one or more prior ITP therapies.

7 Dec 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008

Results out from first phase III randomized clinical trial to study the best time to begin ART in infants

Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine.

19 Nov 2008

Osteoporosis drugs may prevent future bone growth

Patients who start and eventually stop regimens of a common class of osteoporosis drugs called bisphosphonates may be unable to benefit from parathyroid hormone (PTH), which can rebuild bone mass lost due to advanced stage osteoporosis. PTH has been proven to increase the volume and strength of the honeycomb-like bone infrastructure, the inner mesh that begins to diminish in old age.

13 Nov 2008

GlaxoSmithKline to acquire Genelabs Technologies

GlaxoSmithKline has announced that Gemstone Acquisition Corporation, a wholly-owned subsidiary of GSK, is commencing a cash tender offer to purchase all outstanding shares of common stock of Genelabs Technologies, Inc., for $1.30 in cash without interest and less any required withholding taxes.

12 Nov 2008

GSK initiates major seasonal influenza vaccine efficacy trial

GlaxoSmithKline (GSK) announced today that it has started a worldwide clinical efficacy trial to evaluate an innovative vaccine for the prevention of seasonal influenza.

6 Nov 2008